They still have a chance because OCR-002 is clearly an active agent, and the STOP-HE results likely would've been better if they had given patients a higher dose.
However, the loss of momentum from STOP-HE is a big setback in practical terms for a company like OCRX with modest financial resources.
The biggest problem, IMO, is not that the primary endpoint was missed (p=0.129), but rather that the HR on the primary endpoint was a modest 0.80. If the HR on the primary endpoint had been, say, 0.60, OCRX would be in much better shape even if the primary endpoint had been missed. A trial with HR=0.60 (instead of HR=0.80) on the primary endpoint would've had a decent chance to serve as one of the two pivotal trials for FDA approval in this orphan indication, while the actual STOP-HE trial has little such chance, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.